AngioDynamics' VenaCure EVLT™System for Varicose Veins To Be Featured On 'The Doctors' National Television Program
ALBANY, N.Y. April 29, 2010 - AngioDynamics (NASDAQ: ANGO) announced today that on Friday, April 30, the company's VenaCure EVLT varicose vein laser treatment system is expected to be featured in a segment on the popular television show "The Doctors."
"The Doctors" is a one-hour, syndicated daytime television program that provides information from a panel of four practicing medical professionals on a range of contemporary health topics. Varicose and spider veins are of continued interest to viewers as an estimated 80 million women and men in the U.S. suffer from these conditions and could benefit from treatment.
The profiled VenaCure EVLT system is now available with a new NeverTouch laser fiber - expected to be featured in the segment - with a gold tip or jacket that serves as a buffer between the end of the fiber and vein walls, protecting the patient from accidental vein perforation and increasing the tip's visibility for the doctor under ultrasound. In addition to the gold tip, the end of the NeverTouch fiber is covered with a glass tube - or ferrule -that defuses the energy delivered by 56 percent, so it is less likely to cut the vein and will seal it as intended. The ferrule is covered by the gold jacket.
Dr. J. Joseph Hewett of the Los Angeles Vascular Center is expected to explain the procedure during the segment and will be shown performing the VenaCure EVLT laser procedure on a patient who suffers from varicose veins. Dr. Hewett, who practices diagnostic radiology as well as interventional radiology, is part of a movement of leading physicians who are now using the VenaCure EVLT system and the gold-tip NeverTouch fiber to better serve their patients.
"Although Varicose veins are extremely common, patients are often unaware of the fast and effective treatment options now available, making the upcoming segment of 'The Doctors' an important step toward informing patients about the condition and advances represented by the VenaCure EVLT procedure," said Shawn McCarthy, Senior Vice President and General Manager for AngioDynamics' Peripheral Vascular Division.
Initial clinical experience with the NeverTouch fiber shows patients benefiting from less pain and bruising than with a bare-tip laser fiber system. Previous to the VenaCure EVLT gold-tip laser fiber, manufacturers attempted to reduce bruising and pain by either altering the wavelength of the light produced by the laser, or changing how quickly or slowly the fiber was drawn through the vein.
Local listings and times for "The Doctors," which vary, are available at: http://bit.ly/VenaCureEVLTonTV.
For more information about the VenaCure EVLT system, visit www.venacure-evlt.com.
About the VenaCure EVLT Treatment
The VenaCure EVLT procedure uses a minimally-invasive endovenous laser to treat varicose veins, and is a clinically proven alternative to traditional and painful ligation and stripping surgery. It requires no general anesthesia, and offers minimal risk and shorter recovery time. The laser delivers a precise dose of energy into the vein wall, collapsing it. This process, called ablation, cures the condition and diverts blood flow to nearby functional veins. The resulting increased circulation significantly reduces the symptoms of varicose veins and improves their surface appearance.
About AngioDynamics
AngioDynamics is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.AngioDynamics.com.
Safe Harbor
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms" "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2009. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.